Insulin-independent promotion of chemically induced hepatocellular tumor development in genetically diabetic mice

Cancer Science

Volumn 101, Issue 1, 2010, Pages 65-72

  Yamasaki, Kohtaro ^a   Hayashi, Yoshihiro ^a   Okamoto, Sumika ^a   Osanai, Makoto ^a   Lee, Gang Hong ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 PHOSPHOFRUCTO 2 KINASE; DIETHYLNITROSAMINE; HUMAN INSULIN; SOMATOMEDIN BINDING PROTEIN 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; C57BL 6 MOUSE; CANCER RISK; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; GENE MUTATION; HETEROZYGOTE; HYPERINSULINEMIA; INSULIN DEFICIENCY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR PROMOTION; TUMOR VOLUME;

ANIMALS; DIABETES COMPLICATIONS; DIETHYLNITROSAMINE; GERM-LINE MUTATION; INSULIN; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; PHOSPHOFRUCTOKINASE-2;

EID: 71849107123     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01345.x     Document Type: Article

References (49)

1. Bréchot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004, 127:S56-61.
2. Liang TJ, Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 2004, 127:S62-71.
3. Lawson DH, Gray JM, McKillop C, Clarke J, Lee FD, Patrick RS. Diabetes mellitus and primary hepatocellular carcinoma. Q J Med 1986, 61:945-55.
4. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126:460-8.
5. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006, 4:369-80.
6. Strickler HD, Wylie-Rosett J, Rohan T. The relation of type 2 diabetes and cancer. Diabetes Technol Ther 2001, 3:263-74.
7. Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006, 166:1871-7.
8. Kuriki K, Hirose K, Tajima K. Diabetes and cancer risk for all and specific sites among Japanese men and women. Eur J Cancer Prev 2007, 16:83-9.
9. Wang CS, Yao WJ, Chang TT, Wang ST, Chou P. The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses. Cancer Epidemiol Biomarkers Prev 2009, 18:2054-60.
10. Schiel R, Beltschikow W, Steiner T. Diabetes, insulin, and risk of cancer. Methods Find Exp Clin Pharmacol 2006, 28:169-75.
11. Frasca F, Pandini G, Sciacca L, Stein G. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 2008, 114:23-37.
12. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol 2003, 157:1092-100.
13. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005, 293:194-202.
14. Dombrowski F, Bannasch P, Pfeifer U. Hepatocellular neoplasms induced by low-number pancreatic islet transplants in streptozotocin diabetic rats. Am J Pathol 1997, 150:1071-87.
15. Dombrowski F, Mathieu C, Evert M. Hepatocellular neoplasms induced by low-number pancreatic islet transplants in autoimmune diabetic BB/Pfd rats. Cancer Res 2006, 66:1833-43.
16. Lauder I, Abascal J, Cartwright RA, Farndon JR, Johnston IDA. Liver tumours following streptozotocin administration in rats and the effects of pancreatic islet cell transplantation. Carcinogenesis 1981, 2:799-803.
17. Bell RH, Hye RJ, Miyai K. Streptozotocin-induced liver tumors in the Syrian hamster. Carcinogenesis 1984, 5:1235-8.
18. Gabridge MG, Denunzio A, Legator MS. Microbial mutagenicity of streptozotocin in animal-mediated assays. Nature 1969, 221:68-70.
19. Yoshioka M, Kayo T, Ikeda T, Koizumi A. A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes 1997, 46:887-94.
20. Wang J, Takeuchi T, Tanaka S. A mutation in the insulin 2 gene induces diabetes with severe pancreatic β-cell dysfunction in the Mody mouse. J Clin Invest 1999, 103:27-37.
21. Lee G-H, Nomura K, Kitagawa T. Comparative study of diethylnitrosamine-initiated two-stage hepatocarcinogenesis in C3H, C57BL and BALB mice promoted by various hepatopromoters. Carcinogenesis 1989, 10:2227-30.
22. Lee G-H, Nomura K, Kanda H. Strain specific sensitivity to diethylnitrosamine-induced carcinogenesis is maintained in hepatocytes of C3H/HeN ↔ C57BL/6N chimeric mice. Cancer Res 1991, 51:3257-60.
23. Poole TM, Drinkwater NR. Hormonal and genetic interactions in murine hepatocarcinogenesis. Prog Clin Biol Res 1995, 391:187-94.
24. Lee G-H, Ooasa T, Osanai M. Mechanism of the paradoxical, inhibitory effect of phenobarbital on hepatocarcinogenesis initiated in infant B6C3F1 mice with diethylnitrosamine. Cancer Res 1998, 58:1665-9.
25. Enzmann H, Edler L, Bannasch P. Simple elementary method for the quantification of focal liver lesions induced by carcinogens. Carcinogenesis 1987, 8:231-5.
26. Lee G-H. Correlation between Bcl-2 expression and histopathology in diethylnitrosamine-induced mouse hepatocellular tumors. Am J Pathol 1997, 151:957-62.
27. Ito T, Mitui H, Udaka N. Ki-67 (MIB 5) immunostaining of mouse lung tumors induced by 4-nitroquinoline 1-oxide. Histochem Cell Biol 1998, 110:589-93.
28. Frankfurt OS, Robb JA, Sugarbaker EV, Villa L. Monoclonal antibody to single-stranded DNA is a specific and sensitive cellular marker of apoptosis. Exp Cell Res 1996, 226:387-97.
29. Maronpot RR, Haseman JK, Boorman GA, Eustis SE, Rao GN, Huff JE, Chambers PL, Henschler D, Oesch F. Liver lesions in B6C3F1 mice: The National Toxicology Program, experience and position. Mouse Liver Tumors 1987, 10-26. In, eds, Berlin, Springer-Verlag
30. Sakakibara R, Kato M, Okamura N. Characterization of a human placental fructose-6-phosphate, 2-kinase/fructose-2,6-bisphosphatase. J Biochem (Tokyo) 1997, 122:122-8.
31. Atsumi T, Chesney J, Metz C. High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res 2002, 62:5881-7.
32. Pollak M, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004, 4:505-18.
33. Pollak M. Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab 2008, 22:625-38.
34. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer 2006, 94:1221-5.
35. Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol 2006, 207:12-22.
36. Pavelić K, Slijepcević M, Pavelić J. Growth and treatment of Ehrlich tumor in mice with alloxan-induced diabetes. Cancer Res 1979, 39:1807-13.
37. Frey S, Buchmann A, Bursch W, Schulte-Hermann R, Schwarz M. Suppression of apoptosis in C3H mouse liver tumors by activated Ha-ras oncogene. Carcinogenesis 2000, 21:161-6.
38. Calvo MN, Bartrons R, Castaño E, Perales JC, Navarro-Sabaté A, Manzano A. PFKFB3 gene silencing decreases glycolysis, induces cell-cycle delay and inhibits anchorage-independent growth in HeLa cells. FEBS Lett 2006, 580:3308-14.
39. Collier JJ, Scott DK. Sweet changes: glucose homeostasis can be altered by manipulating genes controlling hepatic glucose metabolism. Mol Endocrinol 2004, 18:1051-63.
40. Riu E, Bosch F, Valera A. Prevention of diabetic alterations in transgenic mice overexpressing Myc in the liver. Proc Natl Acad Sci USA 1996, 93:2198-202.
41. Zhang XK, Huang DP, Chiu DK, Chiu JF. The expression of oncogenes in human developing liver and hepatomas. Biochem Biophys Res Commun 1987, 142:932-8.
42. Strom SC, Faust JB. Oncogene activation and hepatocarcinogenesis. Pathobiology 1990, 58:153-67.
43. Kutami R, Nakashima Y, Nakashima O, Shiota K, Kojiro M. Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol 2000, 33:282-9.
44. Hursting SD, Nunez NP, Varticovski L, Vinson C. The obesity-cancer link: lessons learned from a fatless mouse. Cancer Res 2007, 67:2391-3.
45. Bråkenhielm E, Veitonmäki N, Cao R. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 2004, 101:2476-81.
46. Nunez NP, Oh W-J, Rozenberg J. Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation. Cancer Res 2006, 66:5469-76.
47. Ablamunits V, Cohen Y, Brazee IB, Gaetz HP, Vinson C, Klebanov S. Susceptibility to induced and spontaneous carcinogenesis is increased in fatless A-ZIP/F-1 but not in obese ob/ob mice. Cancer Res 2006, 66:8897-902.
48. Schiel R, Müller UA, Braun A, Stein G, Kath R. Risk of malignancies in patients with insulin-treated diabetes mellitus: results of a population-based trial with 10-year follow-up (JEVIN). Eur J Med Res 2005, 10:339-44.
49. Hudacko RM, Manoukian AV, Schneider SH, Fyfe B. Clinical resolution of glycogenic hepatopathy following improved glycemic control. J Diabetes Complications 2008, 22:329-30.